FDA Psychedelic Trials Update: Where MDMA and Psilocybin Stand in 2026

FDAMDMApsilocybinclinical trials2026psychedelic therapy

The last two years have brought more regulatory action on psychedelic therapies than the previous two decades combined. For patients and clinicians following this space, keeping up with what has actually happened — versus what advocates hoped would happen — matters a great deal. Here is a factual summary of where things stand in mid-2026.

The MDMA Story: A Setback and a Path Forward

In August 2024, the FDA issued a Complete Response Letter (CRL) to Lykos Therapeutics (formerly MAPS PBC) for their MDMA-assisted therapy application for post-traumatic stress disorder (PTSD). A CRL does not mean approval is permanently denied — it means the FDA requires additional information before it can approve the application.

The FDA’s advisory committee had voted in June 2024 that the available data did not adequately demonstrate efficacy, and raised concerns about functional unblinding (participants in trials could often tell whether they received MDMA or placebo) and the generalizability of results. The committee also noted questions about therapist conduct in some trial sites.

Lykos has indicated they are conducting a new Phase 3 trial per the FDA’s guidance. That trial is ongoing. Realistically, a resubmission, FDA review period, and potential approval or further feedback cycle means approval for MDMA therapy — if it comes — is unlikely before 2027 at the earliest. Anyone seeing marketing claims that MDMA therapy is “coming soon” or “FDA-approved” should treat them with skepticism.

The FDA’s published guidance on psychedelic drug development is available on their website at FDA.gov.

Psilocybin: Multiple Programs, No Approval Yet

Psilocybin has received Breakthrough Therapy designation from the FDA for treatment-resistant depression (through Compass Pathways) and for major depressive disorder (through Usona Institute). Breakthrough Therapy designation speeds up the development and review process but does not guarantee approval.

Compass Pathways completed a Phase 2b trial of COMP360 (a synthetic psilocybin formulation) and published results showing meaningful response rates at higher doses. Their Phase 3 program is underway at multiple sites across the US and Europe. Usona’s Phase 3 trial for MDD is also enrolling.

Several academic centers — including Johns Hopkins, NYU, and UC San Francisco — continue to publish research on psilocybin for depression, end-of-life anxiety, OCD, and alcohol use disorder. This research informs the regulatory process but is separate from the pharmaceutical approval pathway.

No psilocybin product has an active NDA under FDA review as of mid-2026. Approval timelines are genuinely uncertain; regulatory staff have said publicly they are committed to following the science, and both sponsors and advocates recognize that the advisory committee concerns about MDMA have raised the bar for psychedelic trial design across the board.

What Active Trials Mean for Patients

For patients with treatment-resistant conditions who want to access psilocybin or MDMA legally, clinical trial enrollment is the realistic pathway today. This is more accessible than many people assume:

  • Trials often cover the cost of the investigational drug and some associated care
  • Eligibility criteria vary but many trials include participants who have not responded to multiple standard treatments
  • Geographic availability has expanded — academic medical centers in most major metro areas have active study sites

To find trials, the best starting point is ClinicalTrials.gov. Search for “psilocybin depression” or “MDMA PTSD” and filter by your state. Your psychiatrist can help you understand whether your diagnosis and medication history make you a good candidate.

The State-Level Picture in 2026

Oregon’s Measure 109 psilocybin services framework has now been operating for several years. Licensed facilitators can provide supervised psilocybin sessions to adults 21 and older at licensed service centers. This is not a medical treatment — facilitators are not clinicians and cannot diagnose or treat conditions. Many people use Oregon services for wellness, personal growth, or as a complement to ongoing therapy.

Colorado’s Proposition 122 framework is in earlier stages, with licensing of facilitators and healing centers expanding in 2025-2026. The Colorado framework also covers several other psychedelics beyond psilocybin (ibogaine, mescaline not from peyote, and DMT).

No other US state has enacted a regulated psychedelic services framework as of 2026, though legislative efforts are active in several states.

Staying Oriented in a Fast-Moving Field

The most common mistake people make when researching this space is relying on advocacy-adjacent sources that present hoped-for timelines as likely ones. The FDA process is genuinely uncertain, and both sponsors and the FDA have incentives to move carefully given the sensitivity of the subject matter.

Reliable sources to track regularly: the FDA’s drug approval database, NIMH’s research programs, and peer-reviewed journals (JAMA Psychiatry, NEJM, and Nature Medicine have all published major psychedelic trials recently).

For anyone actively considering treatment options — not just following the field — the most useful step is a conversation with a psychiatrist who is familiar with the current evidence base. If you’d like help connecting with a provider, reach out here.

This content is for educational purposes only and does not constitute medical advice. Consult a licensed clinician about your specific situation.

Drafted by AI and reviewed by our editorial team. Last updated 2026-05-30.